Bio-Rad Laboratories, Inc.
BIO
$251.15
$0.140.06%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -3.92% | -5.15% | -7.46% | -6.26% | -4.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.92% | -5.15% | -7.46% | -6.26% | -4.68% |
| Cost of Revenue | -4.65% | -6.80% | -7.46% | -2.93% | 0.85% |
| Gross Profit | -3.29% | -3.73% | -7.45% | -8.98% | -9.02% |
| SG&A Expenses | -3.65% | -3.44% | -4.52% | -3.18% | 2.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.78% | -3.65% | -7.31% | -4.18% | 0.77% |
| Operating Income | -18.67% | -14.82% | -8.41% | -18.52% | -30.59% |
| Income Before Tax | -175.56% | -436.92% | -225.36% | -76.54% | 81.93% |
| Income Tax Expenses | -134.16% | -711.44% | -291.32% | -101.88% | 80.24% |
| Earnings from Continuing Operations | -189.38% | -388.81% | -209.45% | -68.57% | 82.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -189.38% | -388.81% | -209.45% | -68.57% | 82.43% |
| EBIT | -18.67% | -14.82% | -8.41% | -18.52% | -30.59% |
| EBITDA | -11.86% | -9.58% | -4.75% | -12.30% | -22.48% |
| EPS Basic | -202.81% | -376.51% | -216.46% | -63.75% | 82.28% |
| Normalized Basic EPS | -19.32% | -14.20% | -1.95% | -10.15% | -18.33% |
| EPS Diluted | -202.54% | -367.40% | -214.24% | -61.34% | 82.27% |
| Normalized Diluted EPS | -19.15% | -13.98% | -1.85% | -10.08% | -18.46% |
| Average Basic Shares Outstanding | -3.41% | -3.47% | -3.01% | -2.56% | -1.93% |
| Average Diluted Shares Outstanding | -3.61% | -3.71% | -3.08% | -2.63% | -1.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
